Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKRONASDAQ:CTICNYSE:PBHNASDAQ:PTCT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKROAkero Therapeutics$54.90-0.9%$45.11$21.02▼$58.40$4.42B-0.161.01 million shs1.10 million shsCTICCTI BioPharma$9.09$9.06$4.01▼$9.10$1.20B0.834.50 million shsN/APBHPrestige Consumer Healthcare$83.51-0.2%$83.85$64.63▼$90.04$4.14B0.45300,438 shs361,903 shsPTCTPTC Therapeutics$50.43-0.8%$47.60$28.72▼$58.38$4.03B0.51870,454 shs657,545 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKROAkero Therapeutics-0.90%+3.66%+43.94%+22.93%+147.74%CTICCTI BioPharma0.00%0.00%0.00%0.00%0.00%PBHPrestige Consumer Healthcare-0.13%-1.90%-6.17%-0.84%+28.58%PTCTPTC Therapeutics-0.83%-0.77%+7.39%-10.95%+41.58%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKROAkero Therapeutics3.6156 of 5 stars3.51.00.04.71.81.70.0CTICCTI BioPharmaN/AN/AN/AN/AN/AN/AN/AN/APBHPrestige Consumer Healthcare3.5002 of 5 stars2.32.00.03.51.51.71.9PTCTPTC Therapeutics4.7002 of 5 stars4.34.00.04.42.60.81.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKROAkero Therapeutics 3.00Buy$82.5050.27% UpsideCTICCTI BioPharma 0.00N/AN/AN/APBHPrestige Consumer Healthcare 2.50Moderate Buy$93.3311.76% UpsidePTCTPTC Therapeutics 2.67Moderate Buy$65.0028.89% UpsideCurrent Analyst Ratings BreakdownLatest CTIC, AKRO, PBH, and PTCT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025PTCTPTC TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$80.005/27/2025AKROAkero TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$63.00 ➝ $64.005/27/2025PTCTPTC TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$68.00 ➝ $74.005/13/2025AKROAkero TherapeuticsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$80.00 ➝ $78.005/9/2025PTCTPTC TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$55.00 ➝ $68.005/8/2025PBHPrestige Consumer HealthcareRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold5/8/2025PTCTPTC TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$56.00 ➝ $42.005/7/2025PTCTPTC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$57.00 ➝ $58.005/7/2025PTCTPTC TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$70.00 ➝ $66.005/7/2025PTCTPTC TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$113.00 ➝ $112.005/7/2025PTCTPTC TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$75.00 ➝ $67.00(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/ACTICCTI BioPharma$53M22.62N/AN/A($0.14) per share-64.93PBHPrestige Consumer Healthcare$1.14B3.63$5.20 per share16.05$37.04 per share2.25PTCTPTC Therapeutics$806.78M4.95N/AN/A($14.24) per share-3.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKROAkero Therapeutics-$252.06M-$1.95N/AN/AN/AN/A-15.19%-13.97%8/8/2025 (Estimated)CTICCTI BioPharma-$92.99M-$0.58N/A26.74N/A-91.38%N/A-55.82%N/APBHPrestige Consumer Healthcare$214.60M$4.2919.4717.542.5118.86%12.87%6.78%8/6/2025 (Estimated)PTCTPTC Therapeutics-$363.30M$6.517.75N/AN/A33.56%-78.56%32.11%8/6/2025 (Estimated)Latest CTIC, AKRO, PBH, and PTCT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2025Q1 2025AKROAkero Therapeutics-$1.01$0.90+$1.91$0.90N/AN/A5/8/2025Q4 2025PBHPrestige Consumer Healthcare$1.30$1.32+$0.02$1.00$289.36 million$296.52 million5/6/2025Q1 2025PTCTPTC Therapeutics$0.85$10.04+$9.19N/A$437.16 million$1.18 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKROAkero TherapeuticsN/AN/AN/AN/AN/ACTICCTI BioPharmaN/AN/AN/AN/AN/APBHPrestige Consumer HealthcareN/AN/AN/AN/AN/APTCTPTC TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKROAkero Therapeutics0.0316.8016.80CTICCTI BioPharmaN/A1.271.26PBHPrestige Consumer Healthcare0.554.202.82PTCTPTC TherapeuticsN/A3.893.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKROAkero TherapeuticsN/ACTICCTI BioPharma91.45%PBHPrestige Consumer Healthcare99.95%PTCTPTC TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAKROAkero Therapeutics7.07%CTICCTI BioPharma7.61%PBHPrestige Consumer Healthcare1.60%PTCTPTC Therapeutics5.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKROAkero Therapeutics3079.72 million74.08 millionOptionableCTICCTI BioPharma127131.88 million121.84 millionOptionablePBHPrestige Consumer Healthcare54049.42 million48.62 millionOptionablePTCTPTC Therapeutics1,41079.26 million74.90 millionOptionableCTIC, AKRO, PBH, and PTCT HeadlinesRecent News About These CompaniesPTC Therapeutics (NASDAQ:PTCT) Now Covered by Analysts at Truist FinancialJune 19 at 1:43 AM | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 18 at 12:35 PM | globenewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 17 at 10:00 AM | prnewswire.comTruist Financial Begins Coverage on PTC Therapeutics (NASDAQ:PTCT)June 17 at 8:43 AM | marketbeat.comPTCT Investors Have Opportunity to Join PTC Therapeutics, Inc. Fraud Investigation with the Schall Law FirmJune 16 at 7:03 PM | businesswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 16 at 5:15 PM | accessnewswire.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Stake Lowered by Assenagon Asset Management S.A.June 14, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 13, 2025 | accessnewswire.comPallas Capital Advisors LLC Makes New $353,000 Investment in PTC Therapeutics, Inc. (NASDAQ:PTCT)June 13, 2025 | marketbeat.comPTC Therapeutics, Inc. (NASDAQ:PTCT) Shares Acquired by GAMMA Investing LLCJune 13, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 12, 2025 | prnewswire.comHarbor Capital Advisors Inc. Cuts Stock Holdings in PTC Therapeutics, Inc. (NASDAQ:PTCT)June 12, 2025 | marketbeat.comAnalysts Issue Forecasts for PTCT FY2026 EarningsJune 12, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 11, 2025 | accessnewswire.comBrokers Offer Predictions for PTCT FY2026 EarningsJune 10, 2025 | marketbeat.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 9, 2025 | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 7, 2025 | prnewswire.comAll You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to BuyJune 6, 2025 | zacks.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCTJune 6, 2025 | globenewswire.comWilliam Blair Cuts Earnings Estimates for PTC TherapeuticsJune 6, 2025 | marketbeat.comPublic Employees Retirement System of Ohio Sells 17,657 Shares of PTC Therapeutics, Inc. (NASDAQ:PTCT)June 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCTIC, AKRO, PBH, and PTCT Company DescriptionsAkero Therapeutics NASDAQ:AKRO$54.90 -0.50 (-0.90%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$55.26 +0.36 (+0.65%) As of 06/18/2025 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.CTI BioPharma NASDAQ:CTICCTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.Prestige Consumer Healthcare NYSE:PBH$83.51 -0.17 (-0.20%) Closing price 06/18/2025 03:59 PM EasternExtended Trading$83.75 +0.23 (+0.28%) As of 06/18/2025 05:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.PTC Therapeutics NASDAQ:PTCT$50.43 -0.42 (-0.83%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$50.44 +0.01 (+0.02%) As of 06/18/2025 07:11 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Chime’s Smart IPO: Half the Valuation, Double the Strength Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Tesla Bulls and Bears Collide: What Investors Should Know Qualcomm: A Technical Setup Is Emerging, and It's Bullish 330% Returns YTD: Is CoreWeave's Momentum Softening? Why Quantum Computing Inc. Is the Quiet Winner in Quantum Stocks 3 Catalysts in 7 Days: Archer's Growth Story Just Accelerated Microsoft-OpenAI Rift May Cap Stock Upside Potential Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
